InvestorsHub Logo
Followers 50
Posts 9241
Boards Moderated 1
Alias Born 10/25/2007

Re: None

Wednesday, 04/11/2018 2:05:35 AM

Wednesday, April 11, 2018 2:05:35 AM

Post# of 203921
“The cannabis industry in the U.S. and Europe is characterized by the lack of uniformity and standardization,” Tamir Gedo, CEO of BOL Pharma, an Israeli developer of cannabinoid pharmaceuticals, told Calcalist in an interview Sunday. BOL Pharma is set to launch sales in Israel on April 20. “The lack of industry standards and regulation prevents pharma and biotech companies from entering the field of cannabis,” Mr. Gedo said, adding that the new reform is about to change that. “There are more clinical trials for cannabis medicine taking place in Israel today than in the U.S. and Europe combined,” Mr. Gedo said. “This mass of clinical trials could bring to market four to six new cannabis medicines.”

OWC$$$$$

https://www.calcalistech.com/ctech/articles/0,7340,L-3735706,00.html